• HR+/HER2 neg6
• HER2+0
• TNBC0

• Protocols

• UW20035

  OPEN TO ACCRUAL

  HER2- AR+ Metastatic Breast Cancer PSMA (ICTR# 17072)
  
  

• UW24161

  OPEN TO ACCRUAL

  REDEFINE Study, TBR 22-07
  
  

• UW25099

  OPEN TO ACCRUAL

  Ph 1 Study of MEN2312, a KAT6 Inhibitor, as Monotherapy & in Combination in Pts w/ Adv Breast Cancer